Home › Heart Valve Diseases › NCT07843004
Capitalizing on AI to CapTure Undiagnosed Structural Heart Disease
Who can join
Ages 40 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * 40 years of age or older * Received an ECG upon presentation to the Emergency Department Exclusion Criteria: * Had an echocardiogram within the prior 2 years. * Has a history of structural heart disease. * Not able to receive follow-up based on Community Tele-Paramedicine care manager review. * Quality of life will not improve over the next five years.
About the study
Doctors are testing a new tool called EchoNext to see if it can help find heart problems earlier. EchoNext looks at the heart's electrical test, called an ECG, and uses artificial intelligence (AI) to check for signs of structural heart disease (SHD). SHD includes conditions like weak heart pumping, heart valve problems, or extra thickening of the heart muscle. These problems are common but often go undiagnosed until they cause serious issues like heart failure or stroke.
The main questions this study will answer are:
Can EchoNext alerts help emergency doctors find hidden heart problems sooner?
Does this lead to more follow-up heart tests, like an echocardiogram (heart ultrasound)?
What this means for patients: If a person has an ECG in the Emergency Department, the EchoNext tool may be used to check their heart. If the tool finds something unusual, their doctor may receive an alert and may then recommend further heart tests or follow-up care.
This study will help researchers learn if using EchoNext improves early diagnosis and treatment of heart disease.
What is being tested
- EHR Alert (device)
Sponsor: Pierre Elias · Participants: 4,000 · Started: Sep 16, 2026
Contact the study team
- Michelle S Castillo, MS · Phone: 7322777644
Official record on ClinicalTrials.gov — NCT07843004
Locations in the U.S.
| New York | Columbia University Irving Medical Center / NewYork-Presbyterian, New York |
Conditions
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.